{"id":4591,"date":"2021-05-04T13:13:00","date_gmt":"2021-05-04T11:13:00","guid":{"rendered":"https:\/\/fhu-premimpact.org\/?post_type=publication&#038;p=4591"},"modified":"2021-11-30T13:16:42","modified_gmt":"2021-11-30T12:16:42","slug":"evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2","status":"publish","type":"publication","link":"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/","title":{"rendered":"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients"},"content":{"rendered":"\n<h4 class=\"wp-block-heading\">Abstract<\/h4>\n\n\n\n<p><strong>Background:&nbsp;<\/strong>The criteria for antiphospholipid syndrome (APS) include severe preeclampsia and\/or placental insufficiency leading to preterm delivery before 34 weeks of gestation, but this APS manifestation has been rarely studied. Thus, we report a series of severe preeclampsia occurred in patients with APS.<\/p>\n\n\n\n<p><strong>Methods:&nbsp;<\/strong>We retrospectively analysed data of women with APS (Sydney criteria) who experienced severe preeclampsia with delivery before 34 weeks&#8217; gestation between 2000 and 2017 at five French internal medicine departments and one Italian rheumatology unit.<\/p>\n\n\n\n<p><strong>Results:&nbsp;<\/strong>The 40 women had a mean age of 30.5 \u00b1 4.6 years at their first episode of preeclampsia; 21 were nulligravid (52.5%), 12 (30%) had already been diagnosed with APS, and 21 (52.5%) had a triple-positive antiphospholipid (aPL) antibody test. Preeclampsia occurred at a median gestational age of 25.5 weeks (IQR 23-29). It was associated with HELLP in 18 cases (45%), eclampsia in 6 (15%), placental abruption in 3 (7.5%), catastrophic APS in 3 (7.5%), and foetal and neonatal death in 11 and 15 cases. Overall, 14 (35%) children survived, born at a median gestational age of 31 weeks. Among other APS criteria, 16 women (40%) experienced at least one thrombosis, 17 (42.5%) an intrauterine foetal death, and 19 (47.5%) at least one episode of HELLP during follow-up (median 5 years, IQR = 2-8). None had three or more consecutive miscarriages. Notably, 12 women (30%) had systemic lupus erythematosus.<\/p>\n\n\n\n<p><strong>Conclusions:&nbsp;<\/strong>Severe preeclampsia led to high mortality in the offspring. Almost half of these women experienced other APS features, but not three consecutive miscarriages.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Arthritis Res Ther. 2021 May 4;23(1):134. doi: 10.1186\/s13075-021-02518-7. PMID: 33947469; PMCID: PMC8094564.<\/p>\n","protected":false},"featured_media":0,"template":"","class_list":["post-4591","publication","type-publication","status-publish","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients - FHU Prem&#039;IMPACT<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients - FHU Prem&#039;IMPACT\" \/>\n<meta property=\"og:description\" content=\"Arthritis Res Ther. 2021 May 4;23(1):134. doi: 10.1186\/s13075-021-02518-7. PMID: 33947469; PMCID: PMC8094564.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/\" \/>\n<meta property=\"og:site_name\" content=\"FHU Prem&#039;IMPACT\" \/>\n<meta property=\"article:modified_time\" content=\"2021-11-30T12:16:42+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/\",\"name\":\"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients - FHU Prem&#039;IMPACT\",\"isPartOf\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\"},\"datePublished\":\"2021-05-04T11:13:00+00:00\",\"dateModified\":\"2021-11-30T12:16:42+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\",\"item\":\"https:\/\/fhu-premimpact.org\/en\/publications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#website\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"name\":\"FHU PREM'IMPACT\",\"description\":\"Perinatal inflammation and prematurity\",\"publisher\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#organization\",\"name\":\"FHU PREM'IMPACT\",\"url\":\"https:\/\/fhu-premimpact.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"contentUrl\":\"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg\",\"width\":1280,\"height\":720,\"caption\":\"FHU PREM'IMPACT\"},\"image\":{\"@id\":\"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.instagram.com\/fhupremimpact\/\",\"https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients - FHU Prem&#039;IMPACT","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/","og_locale":"en_US","og_type":"article","og_title":"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients - FHU Prem&#039;IMPACT","og_description":"Arthritis Res Ther. 2021 May 4;23(1):134. doi: 10.1186\/s13075-021-02518-7. PMID: 33947469; PMCID: PMC8094564.","og_url":"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/","og_site_name":"FHU Prem&#039;IMPACT","article_modified_time":"2021-11-30T12:16:42+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/","url":"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/","name":"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients - FHU Prem&#039;IMPACT","isPartOf":{"@id":"https:\/\/fhu-premimpact.org\/en\/#website"},"datePublished":"2021-05-04T11:13:00+00:00","dateModified":"2021-11-30T12:16:42+00:00","breadcrumb":{"@id":"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/fhu-premimpact.org\/en\/publications\/evaluation-of-the-severe-preeclampsia-classification-criterion-for-antiphospholipid-syndrome-in-a-study-of-40-patients-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/fhu-premimpact.org\/en\/"},{"@type":"ListItem","position":2,"name":"Publications","item":"https:\/\/fhu-premimpact.org\/en\/publications\/"},{"@type":"ListItem","position":3,"name":"Evaluation of the severe preeclampsia classification criterion for antiphospholipid syndrome in a study of 40 patients"}]},{"@type":"WebSite","@id":"https:\/\/fhu-premimpact.org\/en\/#website","url":"https:\/\/fhu-premimpact.org\/en\/","name":"FHU PREM'IMPACT","description":"Perinatal inflammation and prematurity","publisher":{"@id":"https:\/\/fhu-premimpact.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/fhu-premimpact.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/fhu-premimpact.org\/en\/#organization","name":"FHU PREM'IMPACT","url":"https:\/\/fhu-premimpact.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","contentUrl":"https:\/\/fhu-premimpact.org\/wp-content\/uploads\/2025\/03\/logo-grand-centre-fhupremimpact.jpg","width":1280,"height":720,"caption":"FHU PREM'IMPACT"},"image":{"@id":"https:\/\/fhu-premimpact.org\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.instagram.com\/fhupremimpact\/","https:\/\/www.linkedin.com\/in\/fhu-prem-impact-ap-hp-inserm-universit-paris-cit-70b911253\/"]}]}},"uagb_featured_image_src":{"full":false,"thumbnail":false,"medium":false,"medium_large":false,"large":false,"1536x1536":false,"2048x2048":false,"post-thumbnail":false,"twentytwenty-fullscreen":false},"uagb_author_info":{"display_name":"Laurence Lecomte","author_link":"https:\/\/fhu-premimpact.org\/en\/author\/"},"uagb_comment_info":0,"uagb_excerpt":"Arthritis Res Ther. 2021 May 4;23(1):134. doi: 10.1186\/s13075-021-02518-7. PMID: 33947469; PMCID: PMC8094564.","_links":{"self":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication\/4591","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/fhu-premimpact.org\/en\/wp-json\/wp\/v2\/media?parent=4591"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}